SCHEMBL20135172

SCHEMBL20135172

COC(=O)c1ccc(C2(C)NC(=O)NC2=O)cc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TNF P01375 1/20 0.38
CRBN Q96SW2 2/20 0.37
KDM4E B2RXH2 3/20 0.37
MAPT P10636 3/20 0.37
GLA P06280 2/20 0.37
GAA P10253 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
ATM Q13315 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PRF1 P14222 1/20 0.36
DDB1 Q16531 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20134909 0.85 LMNA (0.49) LMNAMEN1KMT2ATNFKDM4E
SCHEMBL1431767 0.74 KDM4E (0.42) LMNAKDM4EMAPTGLAGAA
SCHEMBL20134995 0.73 LMNA (0.49) LMNAMEN1KMT2AKDM4EMAPT
SCHEMBL20135103 0.72 LMNA (0.48) LMNAMEN1KMT2AMAPTALDH1A1
SCHEMBL20134959 0.71 LMNA (0.52) LMNAMEN1KMT2ATNFADAM17
SCHEMBL20135343 0.71 LMNA (0.52) LMNAMEN1KMT2ATNFMAPT
SCHEMBL20135551 0.71 LMNA (0.52) LMNAMEN1KMT2ATNFMAPT
SCHEMBL542564 0.71 LMNA (0.64) LMNAMEN1KMT2AADAM17TNKS
SCHEMBL29688463 0.71 LMNA (0.52) LMNAMEN1KMT2ATNFADAM17
SCHEMBL20134957 0.71 LMNA (0.52) LMNAMEN1KMT2ATNFADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 LMNA 4264/4885MEN1 3735/4885KMT2A 2568/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 LMNA 4113/4885MEN1 2913/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.